PCP
AXSM icon

Perbak Capital Partners’s Axsome Therapeutics AXSM Stock Holding History

Perbak Capital Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$517K Buy
3,058
+1,856
+154% +$321K 0.13% 185
2025
Q4 		$220K Sell
1,202
-5,111
-81% -$714K 0.07% 205
2025
Q3 		$767K Buy
6,313
+1,585
+34% +$179K 0.14% 170
2025
Q2 		$494K Buy
+4,728
New +$501K 0.11% 186

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perbak Capital Partners's AXSM Position: Q1 2026 in Review

Perbak Capital Partners increased its Axsome Therapeutics (AXSM) stake by 154% in Q1 2026, buying an estimated $321K and bringing the position to 3,058 shares worth $517K. The position accounts for 0.13% of the portfolio, ranked #185.

Perbak Capital Partners first reported a position in AXSM in Q2 2025 and has held it in 4 quarters since. The position peaked at $767K in Q3 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Perbak Capital Partners held 3,058 shares of Axsome Therapeutics worth $517K as of Q1 2026.
  • Perbak Capital Partners bought 1,856 Axsome Therapeutics shares in Q1 2026, an estimated $321K.
  • Axsome Therapeutics made up 0.13% of Perbak Capital Partners's portfolio in Q1 2026, its #185 holding.
  • Perbak Capital Partners first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Perbak Capital Partners's Axsome Therapeutics position peaked at $767K in Q3 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.